Healthcare (XLV) vs S&P 500

XLV is the Health Care Select Sector SPDR Fund, tracking the S&P 500 health-care industry sub-set. As of April 2026 the top weights are Eli Lilly at roughly 14.3%, UnitedHealth Group near 7%, Johnson & Johnson around 6.5%, Merck near 5%, AbbVie around 5%, with the top ten holdings representing approximately 53% of fund assets. The expense ratio is 0.09%. The fund holds 60 stocks total. SPY tracks the cap-weighted S&P 500 with health care representing approximately 10.4% of the index in April 2026, down from 13.5% in 2022.

The sectoral mix inside XLV has shifted meaningfully. Pharma has fallen from approximately 50% of the fund in 2018 to roughly 38% in April 2026 as Eli Lilly's GLP-1 franchise scaled and as legacy pharma multiples compressed under Inflation Reduction Act drug-price-negotiation overhang. Managed care has fallen from approximately 17% to 14% on UnitedHealth's 2024-2025 deratings tied to Medicare Advantage utilization spikes. Medical devices and biotech together hold roughly 32%.

Three concurrent drivers explain the 12-percentage-point year-to-date 2026 underperformance versus SPY. First, IRA Maximum Fair Price negotiations for the first ten Part D drugs took effect January 1, 2026, with selected drugs from Bristol Myers Squibb (Eliquis), Merck (Januvia), Johnson & Johnson (Xarelto, Stelara), AbbVie (Imbruvica), and Novo Nordisk (Fiasp/NovoLog) seeing price reductions of 38-79% from their 2023 list prices per CMS. The aggregate revenue impact across XLV components is roughly $5-7 billion in 2026, modest in absolute terms but concentrated in high-margin franchises.

Second, UnitedHealth has declined approximately 18% year-to-date on continued Medicare Advantage utilization concerns and the lingering reputational impact from the December 2024 Brian Thompson assassination and subsequent Optum cyberattack disclosures. UnitedHealth's 7% XLV weight means the single-name drag is roughly 1.3 percentage points. Third, vaccine revenue at Pfizer and Moderna has continued to normalize from COVID-era highs, with Pfizer's COVID franchise revenue down 38% year-on-year in Q1 2026.

Eli Lilly's tirzepatide franchise (Mounjaro for diabetes, Zepbound for weight management) generated approximately $24 billion in 2025 and is on track for $34-38 billion in 2026 per consensus. Novo Nordisk's semaglutide franchise (Ozempic, Wegovy) generated approximately $42 billion in 2025. The two firms together represent the dominant GLP-1 supply, although Novo Nordisk is not in XLV (Danish-listed, foreign-issuer rule).

LLY at 14.3% of XLV means the GLP-1 narrative carries outsized weight in the index. LLY shares are roughly flat year-to-date 2026 after gaining 38% in 2024 and 56% in 2023. The April 2026 setup features GLP-1 franchise economics still expanding but with three overhangs: oral GLP-1 candidates from Pfizer (danuglipron, discontinued December 2023), Roche, and others potentially eroding the duopoly by 2027-2028; CMS Part D coverage decisions for obesity-only indications remaining unresolved; and compounding-pharmacy supply alternatives diluting list-price economics. The pair captures whether LLY's franchise can offset the IRA-and-managed-care drag on the rest of XLV.

Healthcare's historical defensive reputation rests on recession-period drawdowns smaller than the broader market. The 2008 GFC saw XLV fall 30% peak-to-trough versus SPY at 56%. The 2020 COVID flash crash saw XLV fall 25% versus SPY at 34%. The 2022 hiking cycle saw XLV fall 14% versus SPY at 25%. In all three episodes the relative outperformance was 9 to 26 percentage points, the basis for treating healthcare as a defensive allocation.

The pattern broke in 2023-2026. The 2023 calendar year saw XLV gain 0.3% versus SPY at 24%, the worst relative year for healthcare since 1999. The 2024 calendar year saw XLV gain 2.1% versus SPY at 23.3%. Year-to-date 2026 the gap is negative 12 percentage points and tracking. Three structural forces have inverted the relationship: IRA drug-price negotiation reducing pricing power, Medicare Advantage margin compression on utilization normalization, and AI-capex-driven SPY mega-cap concentration that healthcare cannot replicate. The defensive premium has flipped to a regulated-price discount.

Even within the broken pattern, two specific episodes since 2023 show XLV outperforming SPY. The August 2024 vol-mageddon episode saw XLV decline 4% versus SPY at 7% peak-to-trough, with the relative outperformance concentrated in the four highest-quality balance sheets (JNJ, MRK, ABBV, ABT). The March 2026 Iran-war episode saw XLV decline 6% versus SPY at 10%, with similar quality-driven attribution. Both episodes featured short, sharp risk-off events where mega-cap-tech concentration in SPY became a liability.

The operating rule that emerges: XLV functions as a defensive hedge in episodes where the volatility shock is either a geopolitical event or a tech-specific de-rating, but it underperforms in episodes where the shock is a labor-market or earnings-cycle event. The 2026 base case for the rest of the year, dominated by Q1-Q3 mega-cap-tech earnings and the Fed-rate-path debate, sits in the second category. Most cross-asset desks therefore treat XLV as a tactical, episode-specific hedge rather than a strategic defensive allocation in the current regime.

The XLV/SPY ratio currently trades at approximately 0.20 (XLV $148 / SPY $720), near the bottom decile of the 2010-2026 distribution. The ratio has compressed from 0.27 at the 2022 high to the current 0.20, a 26% relative derating that reflects the structural forces discussed. Mean-reversion arguments for long-XLV-short-SPY rest on three potential catalysts: an IRA pause or rollback under any 2027 administration change, a Medicare Advantage utilization reversal as 2024-2025 pent-up demand exhausts, or an AI-capex disappointment that re-rates SPY downward to XLV's current level.

The defensive triggers that would activate a tactical XLV overweight are specific. SPY drawdown of 8% or greater in less than four weeks with a tech-specific catalyst would be the first trigger. Any ANFCI cross above zero with credit-side leadership would be the second. A meaningful softening in claims four-week average above 250,000 sustained would be the third. None of these conditions hold in April 2026, which is the structural reason XLV continues to underperform despite the GLP-1 franchise tailwind. The cleanest read is that healthcare has shifted from a defensive sector to a regulated-price-pressure sector, and the pair pricing reflects that shift accurately.